GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OncoVista Innovative Therapies Inc (OTCPK:OVIT) » Definitions » Shiller PE Ratio

OVIT (OncoVista Innovative Therapies) Shiller PE Ratio : (As of Dec. 04, 2024)


View and export this data going back to 2005. Start your Free Trial

What is OncoVista Innovative Therapies Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


OncoVista Innovative Therapies Shiller PE Ratio Historical Data

The historical data trend for OncoVista Innovative Therapies's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoVista Innovative Therapies Shiller PE Ratio Chart

OncoVista Innovative Therapies Annual Data
Trend Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

OncoVista Innovative Therapies Quarterly Data
Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of OncoVista Innovative Therapies's Shiller PE Ratio

For the Biotechnology subindustry, OncoVista Innovative Therapies's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OncoVista Innovative Therapies's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OncoVista Innovative Therapies's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where OncoVista Innovative Therapies's Shiller PE Ratio falls into.



OncoVista Innovative Therapies Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

OncoVista Innovative Therapies's E10 for the quarter that ended in Sep. 2015 is calculated as:

For example, OncoVista Innovative Therapies's adjusted earnings per share data for the three months ended in Sep. 2015 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Sep. 2015 (Change)*Current CPI (Sep. 2015)
=-0.01/100.3915*100.3915
=-0.010

Current CPI (Sep. 2015) = 100.3915.

OncoVista Innovative Therapies Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
200512 0.000 83.032 0.000
200603 -0.007 84.298 -0.008
200606 -0.005 85.606 -0.006
200609 0.000 85.606 0.000
200612 -0.503 85.142 -0.593
200703 -0.040 86.640 -0.046
200706 -0.070 87.906 -0.080
200709 -0.060 87.964 -0.068
200712 -0.150 88.616 -0.170
200803 -0.130 90.090 -0.145
200806 -0.090 92.320 -0.098
200809 -0.100 92.307 -0.109
200812 -0.090 88.697 -0.102
200903 -0.080 89.744 -0.089
200906 -0.080 91.003 -0.088
200909 -0.060 91.120 -0.066
200912 -0.040 91.111 -0.044
201003 -0.010 91.821 -0.011
201006 -0.030 91.962 -0.033
201009 -0.030 92.162 -0.033
201012 -0.020 92.474 -0.022
201103 -0.040 94.283 -0.043
201106 -0.030 95.235 -0.032
201109 -0.010 95.727 -0.010
201112 -0.030 95.213 -0.032
201203 -0.030 96.783 -0.031
201206 -0.010 96.819 -0.010
201209 -0.020 97.633 -0.021
201212 -0.020 96.871 -0.021
201303 -0.020 98.209 -0.020
201306 -0.010 98.518 -0.010
201309 -0.020 98.790 -0.020
201312 -0.020 98.326 -0.020
201403 -0.010 99.695 -0.010
201406 -0.040 100.560 -0.040
201409 0.010 100.428 0.010
201412 -0.070 99.070 -0.071
201503 -0.010 99.621 -0.010
201506 -0.050 100.684 -0.050
201509 -0.010 100.392 -0.010

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


OncoVista Innovative Therapies  (OTCPK:OVIT) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


OncoVista Innovative Therapies Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of OncoVista Innovative Therapies's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


OncoVista Innovative Therapies Business Description

Traded in Other Exchanges
N/A
Address
14785 Omicron Drive, Suite 104, San Antonio, TX, USA, 78245
OncoVista Innovative Therapies Inc is a biopharmaceutical company. It is engaged in developing anticancer therapies by utilizing tumor-associated biomarkers.
Executives
Alexander Ruckdaeschel director 123 EAST 83RD STREET, APT 3-B, NEW YORK NY 10028
Paul A Mieyal director C/O WEXFORD CAPITAL LP, 411 WEST PUTNAM AVE, SUITE 125, GREENWICH CT 06830
Charles E Davidson 10 percent owner C/O WEXFORD CAPITAL LP, 777 SOUTH FLAGLER DRIVE, SUITE 602, WEST PALM BEACH FL 33401
Wexford Capital Lp 10 percent owner 777 WEST PUTNAM AVENUE, 1ST FLOOR, GREENWICH CT 06830
Joseph Jacobs 10 percent owner C/O WEXFORD CAPITAL LP, 777 SOUTH FLAGLER DRIVE, SUITE 602 EAST, WEST PALM BEACH FL 33401
Wexford Spectrum Trading Ltd 10 percent owner 411 WEST PUTNAM AVENUE, SUITE 125, GREENWICH CT 06830

OncoVista Innovative Therapies Headlines

No Headlines